Search clinical trials for: Epoetin alfa or beta

Total 863 results

Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Anemia

Belgium, Spain, United States, Sweden, Denmark, Taiwan, France, Italy, United Kingdom, New Zealand, South Africa, Hungary, Thailand, Mexico, Poland, Czech Republic, Puerto Rico, Finland, Brazil, Germany, Panama
Western Galilee Hospital-Nahariya

Unknown

Prevention of Contrast Induced Nephropathy by Erythropoietin

Diabetes | Chronic Kidney Insufficiency

Israel
Hoffmann-La Roche

Completed

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Anemia

France, Germany, Italy, United States, Taiwan, Canada, Puerto Rico, Spain, Thailand, Portugal, United Kingdom, Poland
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Anemia

France, Italy, United States, Canada, Germany, Spain, Switzerland, Norway
Giovanni FM Strippoli, MD

Completed

The Clinical Evaluation of the Dose of Erythropoietins Trial (CEDOSE)

Kidney Failure, Chronic

Italy
Hamad Medical Corporation

Completed

Comparison Among Erythropoietin Stimulating Agents

Anemia of End Stage Renal Disease

Qatar
Huiqing Sun
Göteborg University; Zhengzhou University

Enrolling by invitation

Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants (EPO)

Developmental Disabilities
Zhengzhou University
Göteborg University; Zhengzhou Children's Hospital, China

Completed

Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage

Premature Infants

China
Hoffmann-La Roche

Terminated

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Anemia

United States
Hoffmann-La Roche

Completed

A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.

Anemia

France
InCROM Europe Clinical Research

Completed

Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects

Anaemia | Chronic Kidney Failure
Leiden University Medical Center

Completed

PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation

Patients Receiving a Kidney From a Non-Heart-Beating Donor

Netherlands
Bayer

Completed

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (DIALOGUE4)

Renal Insufficiency, Chronic | Anemia

United States, Japan
Bayer

Completed

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (DIALOGUE5)

Renal Insufficiency, Chronic | Anemia

United States, Japan
Affymax
Takeda

Completed

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis (EMERALD 2)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States, Bulgaria, Romania, United Kingdom, Italy, Poland, France, Germany, Spain
Hoffmann-La Roche

Completed

A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies

Anemia

Russian Federation
Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies

Anemia

Bulgaria
Charite University, Berlin, Germany
University Hospital, Strasbourg, France; University of Zurich; Hoffmann-La Roche and other collaborators

Completed

Erythropoietin Treatment in Extremely Low Birth Weight Infants (EPO)

Anemia | Infant, Low Birth Weight

Germany
Hoffmann-La Roche

Completed

An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy

Anemia

Hungary
Hoffmann-La Roche

Completed

A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

Anemia

Italy, Spain, Sweden, Hong Kong, Greece, Ireland, United Kingdom, Portugal, Taiwan, Turkey, France, Germany, Russian Federation, Belgium, Austria, Thailand, Poland, Czech Republic, Denmark, Finland, Norway, Mexico
Hoffmann-La Roche

Completed

An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)

Anemia, Neoplasms

France
Chugai Pharmaceutical

Completed

Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients

Anemia

Japan
Chugai Pharmaceutical

Completed

Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)

Predialysis Patients

Japan
Groupe Francophone des Myelodysplasies

Completed

Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS) (EPO-QoL)

Myelodysplastic Syndromes

France
Hoffmann-La Roche

Completed

An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia

Anemia

Morocco
University Hospital, Grenoble
Roche Pharma AG

Completed

Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB (EPOetCEC)

Myocardial Ischemia

France
University of Cambridge
Hoffmann-La Roche; Roche Foundation of Anemia Research (RoFAR, Switzerland)

Completed

Erythropoietin Therapy for Subarachnoid Hemorrhage

Aneurysmal Subarachnoid Hemorrhage

United Kingdom
Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia

Anemia

Bulgaria
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Anemia

Brazil
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Anemia

Belgium, Italy, Poland, Spain, Hong Kong, Canada, France, Greece, Czech Republic, Austria, Estonia, Hungary, Australia, Germany, Finland
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant

Anemia, Kidney Transplantation

Germany
Hoffmann-La Roche

Completed

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

Anemia

Belgium, France, Germany, Italy, Spain, United States, Australia, Sweden, Denmark, Taiwan, Greece, Netherlands, United Kingdom, South Africa, Switzerland, Austria, Thailand, Poland, Hungary, Russian Federation, Mexico, Czech Republic and more
China Medical University Hospital

Unknown

Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants

Retinopathy of Prematurity | Intraventricular Hemorrhage | Infant, Premature | Leukomalacia, Periventricular

Taiwan
Kind Pharmaceuticals LLC

Active, not recruiting

A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

Renal Anemia

United States
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia

Anemia

Spain
Association pour la recherche sur les Affections...

Completed

Biological Predictive Factors of Response to ESA in Low Risk MDS Patients

Myelodysplastic Syndromes
Hoffmann-La Roche

Completed

A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.

Anemia

China
Hoffmann-La Roche

Completed

A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Anemia

China, Hong Kong
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.

Anemia

Korea, Republic of
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis

Anemia

South Africa
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

Anemia

Belgium
Hoffmann-La Roche

Completed

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Anemia

Italy, Spain, United States, Germany
Hoffmann-La Roche

Completed

A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Anemia

United States
Hoffmann-La Roche

Completed

A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.

Anemia

India
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Anemia

United States, Canada, United Kingdom, Mexico, Poland
Hoffmann-La Roche

Completed

A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia

Anemia

Egypt
Hoffmann-La Roche

Completed

An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)

Kidney Disease, Chronic

Slovenia
Chugai Pharmaceutical

Completed

Clinical Study of R744 to Predialysis Patients

Anemia in Pre-Dialysis Patients

Japan
Hoffmann-La Roche

Completed

Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis

Renal Impairment | Renal Anemia of Chronic Kidney Disease

Germany
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis (IMPACT)

Chronic Kidney Diseases

Israel

3

Subscribe